Edgar Filing: Schenkein David P - Form 4

Schenkein E Form 4 March 05, 2									
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION							OMMISSION	OMB APPROVAL	
Check th if no lon subject t Section Form 4 o Form 5 obligatio may con <i>See</i> Instr	ger o 16. or Filed pur ons tinue.	W MENT OF CHA suant to Section a) of the Public 30(h) of the 1	SECUR 16(a) of th Utility Hole	BENEF RITIES ne Securit ding Con	ICIA ies E npany	xchange y Act of 1	Act of 1934, 1935 or Section	OFF Stimated average burden hours per response 3235-0 January 2 Estimated average burden hours per response	
1(b). (Print or Type	Responses)								
	Address of Reporting	Symbol	S PHARM]	5. Relationship of l Issuer (Check	Reporting Pers	
(Last) C/O AGIOS PHARMAG SIDNEY S'	S CEUTICALS, INC	Middle) 3. Date (Month 03/01/	of Earliest T /Day/Year)	ransaction		-	_X_ Director _X_ Officer (give t below) Chief E		
(Street) 4. If Amendment, Date Origina Filed(Month/Day/Year)				1	-	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip) Ta	ble I - Non-I	Derivative	Secur		ired, Disposed of,	or Beneficial	y Owned
1.Title of Security (Instr. 3)		nsaction Date 2A. Deemed th/Day/Year) Execution Date, if any (Month/Day/Year)			ed of	(D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	03/01/2018		Code V M ⁽¹⁾	Amount 13,000	(D) A	Price \$ 0.3025	13,000	D	
Common stock	03/01/2018		S <u>(2)</u>	2,915	D	\$ 80.38 (3)	10,085	D	
Common stock	03/01/2018		S <u>(2)</u>	10,085	D	\$ 81.3 (4)	0	D	
Common stock							271,772	I	See footnote (5)

Edgar Filing: Schenkein David P - Form 4

Common			See
	79,082	Ι	footnote
stock			(6)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of mDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	ivative Expiration Date urities (Month/Day/Year) quired (A) Disposed of str. 3, 4,		7. Title and Amount of Underlying Securities8(Instr. 3 and 4)5(1)(1)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	\$ 0.3025	03/01/2018		M <u>(1)</u>	13,000	(7)	08/12/2019	Common stock	13,000

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Schenkein David P C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE, MA 02139	Х		Chief Executive Officer					
Signatures								
/s/ William Cook, as Attorney in Fact for Da Schenkein	03/05/2018							
**Signature of Reporting Person			Date					
Explanation of Responses:								

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

Edgar Filing: Schenkein David P - Form 4

- (2) This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$79.80 to \$80.79. The (3) reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$80.80 to \$81.77. The (4) reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

- (5) Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
- (6) Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
- This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a
- (7) performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.